APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

Two main causes of platinum resistance are mutation in the tumor suppressor gene TP53 and drug-induced increase in intracellular glutathione concentration. Mutations in TP53 occur in about 50% of human tumors. APR-246 (PRIMA-1(MET)) is the first clinical-stage compound that reactivates mutant p53 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohell, N, Alfredsson, J, Fransson, Å, Uustalu, M, Byström, S, Gullbo, J, Hallberg, A, Bykov, V J N, Björklund, U, Wiman, K G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669826/
https://www.ncbi.nlm.nih.gov/pubmed/26086967
http://dx.doi.org/10.1038/cddis.2015.143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669826/
https://www.ncbi.nlm.nih.gov/pubmed/26086967
http://dx.doi.org/10.1038/cddis.2015.143

Ejemplares similares